natgillin/translations-raw huggingface dataset:
A method of decoding an image, the method comprising: determining a plurality of maximum coding units from an image and determining a coding unit which is hierarchically split from a maximum coding unit from among the plurality of maximum coding units by using information about a division shape of the coding unit, wherein the information about a division shape is parsed from a bitstream; 
Postupak za dekodiranje slike, te postupak sadrži: određivanje mnoštva kvadrata maksimalnih jedinica kodiranja iz slike i određivanje kvadrata jedinice kodiranja koja je hijerarhijski razdvojena iz maksimalne jedinice kodiranja između mnoštva maksimalnih jedinica kodiranja korištenjem informacija o jedinici kodiranja, pri čemu se informacija o jedinici kodiranja raščlanjuje iz toka bitova; određivanje najmanje jedne jedinice predviđanja koja je podijeljena iz jedinice kodiranja korištenjem informacija o jedinici predviđanja, pri čemu se informacija o jedinici predviđanja raščlanjuje iz toka bitova;
represents an amino acid residue selected from Gln and His, represents an amino acid residue selected from Ile and Lys, represents an amino acid residue having a side chain with an - NH2 group, wherein the -NH2 side chain group is functionalized by - C(O)-R5, wherein R5 may be a moiety comprising up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and/or P, 
predstavlja aminokiselinski ostatak kojeg se bira od Gln, Glu i His, predstavlja aminokiselinski ostatak kojeg se bira od Ile i Lys, predstavlja aminokiselinski ostatak koji ima bočni lanac s -NH2 skupinom, pri čemu skupina -NH2 bočnog lanca je funkcionalizirana s -C(O)-R5, pri čemu R5 može biti dio koji sadrži do 50 ili do 100 ugljikovih atoma i proizvoljno heteroatome odabrane od halogena, N, O, S i/ili P,
alkyl comprises from 1 to 6 carbon atoms; 
alkil sadrži od 1 do 6 atoma ugljika;
cycloalkyl comprises from 3 to 10 carbon atoms; 
cikloalkil sadrži od 3 do 10 atoma ugljika;
The compound according to claim 1 having the formula Ib-1b': and pharmaceutically acceptable salts and solvates thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1. 
Spoj sukladno patentnom zahtjevu 1 da ima formulu Ib-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
The compound according to claim 2 having the formula Ib-1d: and pharmaceutically acceptable salts and solvates thereof, wherein Ar1, Ar2, R1, R2 and R are as defined in claim 1; 
Spoj sukladno patentnom zahtjevu 2 da ima formulu Ib-1d: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje Ar1, Ar2, R1, R2 i R su definirani kao u patentnom zahtjevu 1;
The compound according to claim 3 having the formula Ib-1e: and pharmaceutically acceptable salts and solvates thereof, wherein Ar2, R1, R2 and R are as defined in claim 1; 
Spoj sukladno patentnom zahtjevu 3 koje ima formulu Ib-1e: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje Ar2, R1, R2 i R su definirani kao u patentnom zahtjevu 1;
The compound according to claim 4 having the formula Ib-11: and pharmaceutically acceptable salts and solvates thereof, wherein R is as defined in claim 1; 
Spoj sukladno patentnom zahtjevu 4 koje ima formulu Ib-11: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje R je definiran kao u patentnom zahtjevu 1;
The compound according to claim 1 having the formula Ic-1b': and pharmaceutically acceptable salts and solvates thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1 . 
Spoj sukladno patentnom zahtjevu 1 koje ima formulu Ic-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
The compound according to claim 1 having the formula Id-1b': and pharmaceutically acceptable salts and solvates thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1. 
Spoj sukladno patentnom zahtjevu 1 koje ima formulu Id-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
The compound according to claim 1 having the formula Ie-1b': and pharmaceutically acceptable salts and solvates thereof, wherein D, L2, Ar1, Ar2, R, R1, R2, R3, R3' and R4 are as defined in claim 1. 
Spoj sukladno patentnom zahtjevu 1 koje ima formulu Ie-1b’: [image] i njegove farmaceutski prihvatljive soli i solvati, gdje D, L2, Ar1, Ar2, R, R1, R2, R3, R3’ i R4 su definirani kao u patentnom zahtjevu 1.
A compound according to any of Claims 1 to 20 or a pharmaceutically acceptable salt or solvate thereof for use in the treatment and/or prevention of type II diabetes, obesity, dyslipidemia such as mixed or diabetic dyslipidemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperlipidemia, hypertriglyceridemia, hypoglycemia, hyperglycemia, glucose intolerance, insulin resistance, hyperinsulinemia, hypertension, hyperlipoproteinemia, metabolic syndrome, syndrome X, thrombotic disorders, cardiovascular disease, atherosclerosis and its sequelae including angina, claudication, heart attack, stroke and others, kidney diseases, ketoacidosis, nephropathy, diabetic neuropathy, diabetic retinopathy, nonalcoholic fatty liver diseases such as steatosis or nonalcoholic steatohepatitis (NASH). 
Spoj sukladno bilo kojem od patentnih zahtjeva 1 do 20 ili njegova farmaceutski prihvatljiva sol ili solvat za liječenje i/ili prevenciji dijabetesa tipa II, pretilosti, dislipidemije kao što je miješana ili dijabetička dislipidemija, hiperkolesterolemije, niskog HDL kolesterola, visokog LDL kolesterola, hiperlipidemije, hipertrigliceridemije, hipoglikemije, hiperglikemije, intolerancije glukoze, inzulinske rezistencije, hiperinsulinemije, hipertenzije, hiperlipoproteinemije, metaboličkog sindroma, sindroma X, trombotičkih poremećaja, kardiovaskularne bolesti, ateroskleroze i njenih sekvela uključujući anginu, klaudikaciju, srčani udar, moždani udar i druge, bolesti bubrega, ketoacidoze, nefropatije, dijabetičke neuropatije, dijabetičke retinopatije, nealkoholnih bolesti masne jetre kao što je steatoza ili nealkoholni steatohepatitis (NASH).
CH CH A process for the preparation of a compound of formula Ib-1b' according to claim 2 wherein Ar2 is as defined in claim 2; 
Postupak za pripremu spoja formule Ib-1b’ sukladno patentnom zahtjevu 2 [image] gdje Ar2 je definiran kao u patentnom zahtjevu 2;
step b) being optionally followed by conversion of a compound of formula Ib-1b' to a pharmaceutically acceptable salt or solvate thereof. 
korak b) prema potrebi slijedi pretvaranje spoja formule Ib-1b’ u njegovu farmaceutski prihvatljivu sol ili solvat.
step b) being optionally followed by conversion of a compound of formula Ib-1b' to a pharmaceutically acceptable salt or solvate thereof. 
korak b) prema potrebi slijedi pretvaranjem spoja formule Ib-1b’ u njegovu farmaceutski prihvatljivu sol ili solvat.
the coupling of a compound of formula A according to claim 26 with a compound of formula D according to claim 27, followed by 
povezivanja spoja formule A sukladno patentnom zahtjevu 26 sa spojem formule D sukladno patentnom zahtjevu 27, nakon čega slijedi
step b) being optionally followed by conversion of a compound of formula Ib-1h" to a pharmaceutically acceptable salt or solvate thereof. 
korak b) po izboru slijedi pretvaranje spoja formule Ib-1h" u njegovu farmaceutski prihvatljivu sol ili solvat.
The compound according to claim 1 being (2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koji je (2S,5R)-5-(2-klorofenil)-1-(2’-metoksi-[1,1’-bifenil]-4-karbonil)pirolidin-2-karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-5-(2-klorofenil)-1-(2’-metil-[1,1’-bifenil]-4-karbonil)pirolidin-2- karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethoxypyridin-3-yl)benzoyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-5-(2-klorofenil)-1-(4-(2,6-dimetoksipiridin-3-il)benzoil)pirolidin-2-karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-1-(4-(2,6-dimethoxypyridin-3-yl)benzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-1-(4-(2,6-dimetoksipiridin-3-il)benzoil)-5-(2-fluorofenil)pirolidin-2-karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-5-(2-chlorophenyl)-1-(2',5'-dimethoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-5-(2-klorofenil)-1-(2’,5’-dimetoksi-[1,1’-bifenil]-4-karbonil)pirolidin-2-karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-5-(2-chlorophenyl)-1-(5'-cyano-2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-5-(2-klorofenil)-1-(5’-cijano-2’-metoksi-[1,1’-bifenil]-4-karbonil)pirolidin-2-karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being 2S,5R)-5-(2-chlorophenyl)-1-(5'-cyano-2'-methyl-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je 2S,5R)-5-(2-klorofenil)-1-(5’-cijano-2’-metil-[1,1’-bifenil]-4-karbonil)pirolidin-2-karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-3',4'-dimethoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-5-(2-klorofenil)-1-(2-fluoro-3’,4’-dimetoksi-[1,1’-bifenil]-4-karbonil)pirolidin-2-karboksilna kiselina ili njena farmaceutski prihvatljiva so ili solvat.
The compound according to claim 1 being (2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethoxypyridin-3-yl)-3-fluorobenzoyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-5-(2-klorofenil)-1-(4-(2,6-dimetoksipiridin-3-il)-3-fluorobenzoil)pirolidin-2- karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-1-(4-(2,6-dimethoxypyridin-3-yl)-3-fluorobenzoyl)-5-(2-fluorophenyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-1-(4-(2,6-dimetoksipiridin-3-il)-3-fluorobenzoil)-5-(2-fluorofenil)pirolidin-2- karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
The compound according to claim 1 being (2S,5R)-1-(5'-cyano-2'-methyl-[1,1'-biphenyl]-4-carbonyl)-5-(2,3-difluorophenyl)pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1 koje je (2S,5R)-1-(5’-cijano-2’-metil-[1,1’-bifenil]-4-karbonil)-5-(2,3-difluorofenil)pirolidin-2- karbonska kiselina ili njena farmaceutski prihvatljiva sol ili solvat.
A formulation according to claim 2, wherein the aqueous vehicle is water for infusion. 
Formulacija sukladno patentnom zahtjevu 2, naznačena time što nosač je voda za infuziju.
A formulation according to claim 5, wherein the formulation comprises two or more solubilizers. 
Formulacija sukladno patentnom zahtjevu 5, naznačena time što formulacija sadrži dva ili više solubilizatora.
A formulation according to claim 5 or claim 6, wherein the or each solubilizer is a polyethoxylated fatty acid or a mixture thereof. 
Formulacija sukladno patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačena time što svaki solubilizator je polietoksilirana masna kiselina ili njihova smjesa.
A formulation according to claim 1, wherein the formulation comprises: from 30 % to 95% by volume dimethyl acetamide; 
Formulacija sukladno patentnom zahtjevu 1, naznačena time što formulacija sadrži: od 30 % do 95% volumena dimetil acetamida;
A formulation according to any preceding claim wherein gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is in the form of the (S)-phosphate epimer with a diastereoisomeric purity of greater than 95%. 
Formulacija sukladno bilo kojem od patentnih zahtjeva naznačena time što gemcitabin-[fenil-benzoksi-L-alaninil)]-fosfat je u obliku (S)-fosfat epimera s dijastereoizomerskom čistoćom većom od 95%.
A method of preparing a pharmaceutical formulation of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate being suitable for infusion or injection, the method comprising: 
Postupak za pripremu farmaceutske formulacije gemcitabin-[fenil-benzoksi-L-alaninil)]-fosfata koji je pogodan za infuziju ili injekciju, pri čemu postupak sadrži:
diluting a solution comprising gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate and dimethyl acetamide with an aqueous vehicle to provide the formulation suitable for infusion or injection. 
razblaženje rastvora koji sadrži gemcitabin-[fenil-benzoksi-L-alaninil)]-fosfat i dimetil acetamid sa vodenim nosačem da bi se dobila formulacija pogodna za infuziju ili injekciju.
a first formulation comprising: 
prvu formulaciju koja sadrži:
from 5% to 50% by volume aqueous vehicle; and a second formulation comprising: 
od 5% do 50% prema volumenu vodenog nosača; i drugu formulaciju koja sadrži:
from 20% to 60% by volume a first solubilizer; 
od 20% do 60% prema volumenu prvog solubilizatora;
A kit according to claim 16 or claim 17, wherein gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate is in the form of the (S)-phosphate epimer with a diastereoisomeric purity of greater than 95%. 
Komplet sukladno patentnom zahtjevu 16 ili patentnom zahtjevu 17, naznačen time što gemcitabin-[fenil-benzoksi-L-alaninil)]-fosfat je u obliku (S)-fosfat epimera s dijastereoizomerskom čistoćom većom od 95%.
represents an amino acid residue having a side chain with an -NH2 group, wherein the -NH2 side chain group is functionalized by -C(O)-R5, wherein R5 may be a moiety comprising up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and/or P, 
predstavlja aminokiselinski ostatak koji ima bočni lanac s -NH2 skupinom, pri čemu skupina -NH2 bočnog lanca je funkcionalizirana s -C(O)-R5, pri čemu R5 može biti dio koji sadrži do 50 ili do 100 ugljikovih atoma i proizvoljno heteroatome odabrane od halogena, N, O, S i/ili P,
The compound of any one of claims 1 to 3, which is 
Spoj bilo kojeg od patentnih zahtjeva 1 do 3, koji je [image]
The compound of any one of claims 1, 2 or 9, which is 
Spoj bilo kojeg od patentnih zahtjeva 1, 2 ili 9, koji je [image]
An antibacterial agent comprising an ionic nanostructured complex formed by proteins and/or polypeptides, carbohydrates, salts of alkali and alkaline-earth metals and iodine intercalated into them wherein the proteins and/or polypeptides of the ionic nanostructured complex contain at least one chain-terminal amino acid with electron-donor functional groups. 
Antibakterijsko sredstvo, naznačeno time, da obuhvaća ionski nanostrukturirani kompleks koji je sastavljen od proteina i/ili polipeptida, ugljikohidrata, soli alkalijskih metala ili soli zemnoalkalijskih metala te joda koji se umeće u unutrašnjost njihovih struktura, pri čemu proteini i/ili polipeptidi od ionskog nanostrukturiranog kompleksa, sadrže najmanje jedan završetak amionokiselinskog lanca s funkcionalnim elektron-donorskim skupinama.
The antibacterial agent according to claim 1 wherein the proteins comprise interleukins and the chain-terminal amino acids include Phe, Ala, Val, Leu and Ile. 
Antibakterijsko sredstvo prema zahtjevu 1, naznačeno time, da proteini sadrže interleukine, a završetak aminokiselinskog lanca obuhvaća strukture Phe, Ala, Val, Leu i Ile.
A method of producing the antibacterial agent according to claim 1 or 2 characterized in that it comprises complexation reaction of carbohydrates and proteins with metal salts and intercalation of iodine into the complex at ionic strength from 5.10-4 to 15 wherein the introduction of said proteins is carried out as an individual step after intercalation of 5 to 95 % iodine. 
Postupak proizvodnje antibakterijskog sredstva prema bilo kojem od zahtjeva 1 ili 2, naznačen time, da obuhvaća reakciju strukturiranja kompleksa ugljikohidrata i proteina s metalnim solima i umetnutim jodom u takav kompleks, uz ionsku snagu od 5.10-4 do 15, pri čemu se uvođenje navedenih proteina vrši kao pojedinačna faza nakon prethodnog strukturnog umetanja od 5 do 95% joda.
A pharmaceutical composition characterized in that it comprises the antibacterial agent according to claim 1 or 2 formulated into a dosage form suitable for parenteral, oral, external or other application. 
Farmaceutski sastav, naznačen time, da sastav obuhvaća antibakterijsko sredstvo prema zahtjevu 1 ili 2, formulirano u doznom obliku koji je prikladan za parenteralnu, oralnu, vanjsku ili neku drugu primjenu.
The compound or pharmaceutical acceptable salt of claim 1, wherein X is O. 
Spoj ili farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, naznačeno time što X je O.
The compound or pharmaceutical acceptable salt of claim 1, wherein X is NR5. 
Spoj ili farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, naznačeno time što X je NR5.
The compound or pharmaceutical acceptable salt of claim 1, wherein R5 is carbocyclylalkyl, aralkyl, heterocyclylalkyl, or heteroarylalkyl. 
Spoj ili farmacetska prihvatljiva sol sukladno patentnom zahtjevu 1, naznačeno time što R5 je karbociklilalkil, aralkil, heterociklilalkil ili heteroarilalkil.
A compound of formula (2): 
Spoj sa formulom (2): [image]
The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is suitable for intravenous administration. 
Farmaceutska kompozicija patentnog zahtjeva 3, gdje je farmaceutska kompozicija pogodna za intravensku administraciju.
The pharmaceutical composition of claim 8 or claim 9, wherein the pharmaceutical composition has a pH of from about 4 to about 6. 
Farmaceutska kompozicija patentnog zahtjeva 3 ili patentnog zahtjeva 4, gdje farmaceutska kompozicija ima pH od oko 4 do oko 6.
The pharmaceutical composition of any one of claims 3-5, wherein the pharmaceutical composition has a pH of from about 4 to about 5. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-5, gdje farmaceutska kompozicija ima pH od oko 4 do oko 5.
The pharmaceutical composition of any one of claims 8-10, wherein the pharmaceutical composition has a pH of about 4. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-6, gdje farmaceutska kompozicija ima pH od oko 4.
A kit comprising a compound of claim 1 or claim 2 in dry form or the pharmaceutical composition of any one of claims 3-7 in dry form; and a pharmaceutically acceptable liquid diluent. 
Set koji sadrži spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 u suhoj formi ili farmaceutsku kompoziciju bilo kojeg od patentnih zahtjeva 3-7 u suhoj formi; i farmaceutski prihvatljivo tekuće otapalo.
The compound of claim 1 or claim 2 or the pharmaceutical composition of any one of claims 3-7 for use in the treatment of a cardiovascular disease. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-7 za primjenu u liječenju kardiovaskularne bolesti.
The compound of claim 1 or claim 2 or the pharmaceutical composition of any one of claims 3-7 for use in the treatment of heart failure. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-7 za primjenu u liječenju srčane insuficijencije.
The compound of claim 1 or claim 2 or the pharmaceutical composition of any one of claims 3-7 for use in the treatment of acute decompensated heart failure. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-7 za primjenu u liječenju akutne dekompenzirane srčane insuficijencije.
The compound of claim 1 or claim 2 or the pharmaceutical composition of any one of claims 3-7 for use as defined in any one of claims 9-11, wherein the compound or pharmaceutical composition is to be administered intravenously in an amount ranging from 10 µg compound of formula (1) or (2)/kg/minute to 50 µg of compound of formula (1) or (2)/kg/minute. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-7 za primjenu kao što je definirano u bilo kojem od patentnih zahtjeva 9-11, gdje spoj ili farmaceutska kompozicija se trebaju administrirati intravenski u količini koja je u opsegu od 10 µg spoja sa formulama (1) ili (2)/kg/minuti do 50 µg spoja sa formulama (1) ili (2)/kg/minuti.
A polyester composition comprising: a melt-phase polyethylene terephthalate polyester having incorporated therein residues of a monomer having two or more fused aromatic rings, in an amount from 0.5 mole% to 2.5 mole%, based on a total amount of dicarboxylic acid residues in the melt-phase polyethylene terephthalate polyester comprising 100 mole%; and titanium; wherein the titanium is present in an amount from 3 ppm to 100 ppm titanium atoms, based on the total weight of the polyester composition. 
Poliesterska mješavina, naznačena time što sadrži: talinsku fazu polietilen-tereftalatnog poliestera koja u sebi sadrži uključene ostatke monomera koji ima dva ili više kondenziranih aromatskih prstena, u količini od 0,5%, molarno, do 2,5%, molarno, na osnovi ukupne količine ostataka dikarboksilne kiseline u talinskoj fazi polietilen-tereftalatnog poliestera koju čini 100%, molarno; i titanij; gdje je titanij prisutan u količini od 3 ppm do 100 ppm atoma titanija, na osnovi ukupne težine poliesterske mješavine.
The polyester composition according to claim 1, wherein the polyester composition further comprises residues of phosphoric acid. 
Poliesterska mješavina u skladu s patentnim zahtjevom 1, naznačena time što poliesterska mješavina dodatno sadrži ostatke fosforne kiseline.
The polyester composition according to claim 1, wherein the melt-phase polyethylene terephthalate polyester has an I. V., obtained from a melt-phase polymerization reaction, of at least 0.72 dL/g. 
Poliesterska mješavina u skladu s patentnim zahtjevom 1, naznačena time što dobivena talinska faza polietilen-tereftalatnog poliestera iz talinske faze reakcijom polimerizacije ima I. V. od najmanje 0,72 dl/g.